Related Experiment Videos
Gentamicin-induced ototoxicity in a carefully monitored renal-failure patient
Abstract:
A case of gentamicin-induced ototoxicity, documented by electronystagmography and audiometry, in a patient with chronic renal failure is presented. A 39-year-old white man was hospitalized for a renal transplant procedure. Multiple postoperative complications included infection, and the transplanted kidney was rejected eventually. The patient was carefully monitored with frequent serum gentamicin determinations and subsequent pharmacokinetic analysis throughout the six-week course of therapy. Ototoxicity became apparent 10 days after the discontinuance of gentamicin therapy even though predicted and measured levels never fell outside the range of 1.5 to 6.0 microgram/ml throughout the period of antibiotic administration. A brief review of the presentation of gentamicin ototoxicity with special emphasis on the renal-failure patient is included. Clinicians should be aware of potential toxicities and must be able to recognize those patients at high risk. Patients must be monitored carefully, and a risk-benefit analysis should precede proposed therapy.
Insights
Gentamicin can cause ototoxicity, even at therapeutic levels in patients with chronic renal failure. Careful monitoring and risk-benefit analysis are crucial for this high-risk group.
Area of Science:
- Nephrology
- Ototoxicology
- Pharmacokinetics
Background:
- Gentamicin is a common antibiotic used in patients with chronic renal failure.
- Renal impairment can alter drug metabolism and excretion, increasing the risk of toxicity.
Observation:
- A case study of a 39-year-old male patient who underwent renal transplant.
- The patient received gentamicin for a postoperative infection.
- Ototoxicity manifested 10 days after gentamicin discontinuation, despite therapeutic serum levels.
Findings:
- Electronystagmography and audiometry confirmed gentamicin-induced ototoxicity.
- Serum gentamicin levels remained within the 1.5 to 6.0 microgram/ml range.
- Ototoxicity occurred despite pharmacokinetic monitoring and adherence to therapeutic ranges.
Implications:
- Patients with chronic renal failure are at increased risk for gentamicin ototoxicity.
- Clinicians must be vigilant in monitoring for ototoxicity in this population.
- Risk-benefit assessment and careful patient selection are vital before initiating gentamicin therapy.